P atients with established or stable ischemic heart disease (SIHD) who have had a previous myocardial infarction (MI) demonstrate a range of residual risk for recurrent cardiovascular events. 1 Vorapaxar is a firstin-class antiplatelet agent that inhibits thrombin-mediated activation of platelets via the protease-activated receptor-1. Vorapaxar is effective for secondary prevention among stable patients with established atherothrombosis and has been approved for clinical use in the United States and Europe in patients with previous MI without a history of stroke or transient ischemic attack (TIA). [2] [3] [4] Because of the importance of balancing efficacy against an associated increase in the risk of bleeding, clinical risk stratification has the potential to aid in selecting candidates for treatment with vorapaxar.
Therefore, we sought to identify readily available clinical characteristics that were associated with longterm atherothrombotic risk and that might distinguish a population of patients with established ischemic heart disease in whom the benefit of intensive therapy most clearly outweighs risk. In this analysis, we identify independent clinical predictors of atherothrombotic risk among placebo-treated patients enrolled in the randomized, double-blind TRA 2°P-TIMI 50 [Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50; NCT00526474] and assess a practical risk stratification scheme with respect to the efficacy and safety of vorapaxar.
MethODs study Population and Procedures
The TRA 2°P-TIMI 50 was a multinational, double-blind, randomized, placebo-controlled trial of vorapaxar among 26 449 patients with a history of atherothrombosis. 2 The majority of patients (n=17 779, 67%) were enrolled on the basis of a history of MI within the previous 2 weeks to 12 months. 2, 3 Patients were randomized to vorapaxar sulfate 2.5 mg (vorapaxar 2.08 mg) or placebo orally daily. The ethics committee at each participating center approved the protocol. Written informed consent was obtained from all patients.
Two populations within the TRA 2°P-TIMI 50 trial were used for this analysis. First, baseline clinical characteristics associated with the risk of recurrent major atherothrombotic events were identified in the cohort of patients with a history of MI and complete baseline data randomized to placebo (n=8598). The identified clinical risk indicators were used to assign patients to simple risk categories as described below. Second, the treatment effect with vorapaxar was then determined within risk categories in the subset of patients with previous MI, excluding those with a history of stroke or TIA, representing the US Food and Drug Administration and European Medicines Agency previous-MI approval population for whom there is a clinical indication for vorapaxar (n=16 398 with complete baseline data).
For this analysis, renal dysfunction was defined by a glomerular filtration rate <60 mL·min −1 ·1.73 m −2 estimated with the Modification of Diet in Renal Disease equation.
end Points
The efficacy end point of primary interest for atherothrombotic risk stratification was a composite of cardiovascular death, MI, or ischemic stroke. The safety end point for this analysis was GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) severe bleeding. An end point to assess net clinical outcome was defined previously for this trial and included allcause death, MI, stroke, or GUSTO severe bleeding. 2 All elements of the composite efficacy, bleeding, and net clinical end points were adjudicated according to established definitions by a clinical events committee blinded to treatment allocation. 5 
statistical analysis
Univariable predictors of cardiovascular death, MI, or ischemic stroke in placebo-treated patients who qualified for the trial with previous MI (n=8598) were identified by Cox proportional hazards modeling analysis (details in the Appendix in the online-only Data Supplement). Nine independent baseline clinical atherothrombotic risk indicators were then selected by consistency of forward and backward selection with a significance threshold of P<0.01. On the basis of parameter estimates of similar magnitude, each atherothrombotic risk indicator was weighted evenly to define total risk as the arithmetic sum of risk indicators. What are the clinical implications?
• Risk assessment may be useful to identify high-risk patients with stable ischemic heart disease and previous myocardial infarction who have the greatest potential for benefit from more intensive secondary preventive therapy such as treatment with vorapaxar. • This approach outlines a practical strategy that could be used by clinicians to assist with risk stratification and therapeutic decision making for vorapaxar use for secondary prevention after myocardial infarction and can be considered for application to other populations and therapies.
defined according to the 3-year risk of cardiovascular death, MI or ischemic stroke of <5% (low), 5% to <15% (intermediate), and ≥15% (high), aligning with a total of 0, 1 to 2, and ≥3 risk indicators, respectively. All efficacy analyses were performed by intention to treat with Cox proportional hazards modeling with randomized treatment (vorapaxar versus placebo) and intent to use a thienopyridine (randomization stratification factor) as covariates. Safety analyses included all patients given at least 1 dose of study drug and included events occurring up to 60 days after premature cessation or 30 days after study completion. All presented event rates are 3-year Kaplan-Meier (KM) estimates. We assessed for a heterogeneous treatment effect of vorapaxar using Cox proportional hazards regression modeling including a treatment-by-risk strata interaction term. Confidence intervals for absolute risk reduction (ARR) estimates were calculated. All reported P values are 2 sided. Values of P<0.05 were considered to signify nominal statistical significance with no adjustment for multiple comparisons. All analyses were conducted with Stata/IC version 13.1 (StataCorp LP).
resUlts

Patient Population
The baseline characteristics of the 8598 placebo-treated patients enrolled with previous MI and with complete baseline clinical data are summarized in Table 1 . The median age of patients was 59 years; 20% were women; 22% had diabetes mellitus; 13% had a manifestation of peripheral artery disease; 3.3% had a history of previous stroke; and 12% had renal dysfunction. Adherence to guideline-based therapies was high, with 98% receiving aspirin, 96% receiving a statin, and 84% receiving a β-blocker. Forty-five percent had an MI within 3 months, 29% within 3 to 6 months, and 26% between 6 and 12 months. The median follow-up in this cohort was 30 months (interquartile range, 24-36 months). During follow-up, 724 placebo-treated patients (8.4%) with previous MI experienced at least 1 element of the composite end point of cardiovascular death, MI, or ischemic stroke; 176 (2.0%) suffered a cardiovascular death, 527 (6.1%) had an MI, and 102 (1.2%) suffered an ischemic stroke.
independent Predictors of recurrent atherothrombotic events
Baseline clinical characteristics were evaluated as univariable predictors of recurrent atherothrombotic events in placebo-treated patients with a previous MI (Table 1) . Of these, 9 were identified as independent characteristics associated with atherothrombotic risk: age ≥75 years, diabetes mellitus, hypertension, current smoking, peripheral artery disease, prior stroke, prior coronary artery bypass grafting, history of heart failure, and renal dysfunction (estimated glomerular filtration rate <60 mL·min −1 ·1.73 m −2 ; Table 2 ). Multivariate model param-eters and performance are described further in the Appendix in the online-only Data Supplement.
classification of atherothrombotic risk
Because the parameter estimates for each of the 9 predictor variables were of similar magnitude (Table 2) , a practical approach to the categorization of atherothrombotic risk was taken, using the arithmetic sum of the number of risk indicators present. The distribution of patients across the full range of risk indicators is provided in Figure 1 . This strategy of defining atherothrombotic risk showed a strong, graded association with the composite of cardiovascular death, MI, or ischemic stroke at 3 years in the placebo group (P for trend <0.0001; Figure 1) . A similar, significant pattern of increasing event rates with an increasing number of risk indicators was observed for each of the individual efficacy end points (P for trend <0.0001 for all; Figure I in the online-only Data Supplement).
efficacy of Vorapaxar by Baseline atherothrombotic risk
The efficacy and safety of vorapaxar were assessed in stable patients with previous MI with a clinical indication for vorapaxar (previous MI with no history of stroke or TIA; n=16 398). The graded increase in the risk of recurrent atherothrombotic events with an increasing number of indicators was consistent in placebo-and vorapaxar-treated patients within this population (P for trend <0.0001 for the composite of cardiovascular death, MI, or ischemic stroke and individual component end points except for ischemic stroke with vorapaxar, for which P=0.01).
Risk categories, defined as low (0 risk indicators), intermediate (1-2 risk indicators), and high (≥ 3 risk indicators), represented 19% (n=3217), 61% (n=9967), and 20% (n=3214), of the post-MI approval population, respectively. Whereas the relative risk reduction in cardiovascular death, MI, or ischemic stroke with vorapaxar was not significantly different across the low-, intermediate-, and high-risk groups (4%, 28%, and 22%; P for interaction=0.38), the greater absolute risk in the latter groups led to proportionately greater ARRs ( Table I in the online-only Data Supplement). Specifically, patients without any risk indicators demonstrated no ARR of major cardiovascular events with vorapaxar (3-year KM rate of 3.5% for vorapaxar versus 3.6% for placebo; Figure 2A ). In contrast, among patients with intermediate risk, vorapaxar conferred an ARR of 2.1% (95% confidence interval, 0.9-3.3) compared with placebo (3-year KM rate of 6.0% versus 8.1%), translating into a number needed to treat of 48 to prevent 1 major cardiovascular event by 3 years ( Figure 2B ). Among patients in the high-risk group, vorapaxar demonstrated a ORIGINAL RESEARCH ARTICLE 307 3.2% (95% confidence interval, 0.3-6.1) ARR (KM rate of 17.7% for placebo and 14.5% for vorapaxar) with a number needed to treat of 31 ( Figure 2C ). Similar findings were observed when patients were stratified by time from the qualifying MI to enrollment in the study, with a consistent pattern of increasing benefit across risk groups in patients enrolled 3 or more months after an MI (Figure 3 ). Figure II in the online-only Data Supplement) shows a similar trend of ARR with vorapaxar versus placebo in the high-risk patients for MI (10.7% versus 12.3%; ARR, 1.6%; 95% confidence interval, −0.9 to 4.1), ischemic stroke (1.2% versus 2.5%; ARR, 1.3%; 95% confidence interval, 0.1-2.5), and cardiovascular death (5.4% versus 6.7%; ARR, 1.3%; 95% confidence interval, −0.7 to 3.3). Baseline characteristics were well matched by randomization in patients with previous MI allocated to vorapaxar (n=8644) with clinically minimal differences in the rates of obesity (33% vs 31%), eGFR <60 mL·min −1 ·1.73 m −2 (12% vs 13%), and previous statin (96% vs 95%). Peripheral artery disease includes a history of claudication, ankle-brachial index <0.85, or previous revascularization or amputation. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein, IQR, interquartile range; MI, myocardial infarction; and PCI, percutaneous coronary intervention.
Evaluation of individual efficacy end points (
*Per 1-year increase in age. Figure 2D ), respectively. Rates of fatal bleeding or intracranial hemorrhage were 0.9% (n=10) and 0.9% (n=8) in the high-risk patients treated with vorapaxar and placebo, respectively. The low-risk population had numerically higher rates of GUSTO severe bleeding with vorapaxar (3-year KM rates of 0.7% versus 0.1%; absolute risk difference, −0.6%; 95% confidence interval, −1.1 to 0) without clear efficacy; therefore, the net clinical outcome was less favorable with vorapaxar compared with placebo (3-year KM rate of 4.9% for vorapaxar versus 4.5% for placebo; absolute risk difference, −0.4%; 95% confidence interval, −2.1 to 1.3; Figure 2A and 2D).
Bleeding and net clinical Outcome
DiscUssiOn
The protease-activated receptor-1 antagonist vorapaxar is effective for secondary prevention in stable patients with established atherothrombosis and has been approved for use in patients with previous MI without a history of stroke or TIA. [2] [3] [4] Because the antithrombotic benefit is accompanied by an increased risk of bleeding, the use of vorapaxar for secondary prevention is likely to be based on careful patient selection. We hypothesized that clinical parameters associated with recurrent atherothrombotic events could be useful in selecting high-risk patients with ischemic heart disease in whom the benefit of intensive antiplatelet therapy most clearly outweighs the risk of severe bleeding. We found that 9 routinely assessed clinical characteristics (age, diabetes mellitus, hypertension, smoking, peripheral arterial disease, previous stroke, previous coronary artery bypass graft, history of heart failure, and renal dysfunction) not only established a gradient of risk for recurrent ischemic events but also distinguished a pattern of increasing absolute benefit from treatment with vorapaxar. We also found that patients without any of these baseline risk indicators had an overall unfavorable balance of efficacy and bleeding. Notably, this pattern was consistent regardless of the time from most recent MI. This approach outlines a practical strategy that could be used by clinicians to assist with risk stratification and therapeutic decision making for vorapaxar use for secondary prevention after MI. for disease progression recognized by SIHD practice guidelines as high-risk comorbid conditions warranting particular focus for medical therapy. 6, 7 Notably, despite high rates of adherence to guideline-based therapies in this study, the presence of these risk factors still carried significant risk in our data set. Moreover, the presence of atherosclerosis outside the coronary bed, heart failure, and renal dysfunction are also now well recognized as potent risk indicators across the spectrum of ischemic heart disease. 8 Therefore, using these simple, well-described variables, we were able to identify an ≈5-fold gradient in the risk of recurrent major cardiovascular events across low-, intermediate-, and high-risk categories. Importantly, application of this simple categorization of baseline atherothrombotic risk distinguished a pattern of differential treatment benefit with vorapaxar. Although the rate of bleeding also rises across risk categories, the robust reductions in ischemic events with increasing atherothrombotic risk result in increasing overall net clinical benefit, with ARRs of 2.0% for intermediate-risk and 3.5% for high-risk populations eligible for vorapaxar. However, in the low-risk population, representing ≈20% of the population studied, the risk of severe bleeding did not appear to be offset by the antithrombotic benefit of vorapaxar.
With the intent of maintaining generalizability of the risk indicators to other populations and therapies, the clinical atherothrombotic risk indicators were identified in the full placebo cohort with previous MI, including patients with a history of stroke or TIA. Notably, stroke was a potent predictor of recurrent cardiovascular events, particularly recurrent stroke. Because previous stroke is a contraindication to treatment with vorapaxar, all analyses related to the treatment effect of vorapaxar were restricted to patients eligible for therapy with vorapaxar and therefore excluded patients with a history of previous stroke or TIA. Therefore, the distribution of risk indicators and reported treatment effect is representative of the population of patients with a clinical indication for vorapaxar. For the sake of completeness, a sensitivity analysis excluding previous stroke as a risk indicator was performed in the placebo-treated patients with previous MI ( Figure III in the online-only Data Supplement).
Although concomitant antiplatelet therapy might be expected to be of particular interest in this analysis of patients with previous MI, when we consider the risk of recurrent cardiovascular events and the incremental benefit of adding vorapaxar, neither aspirin use nor thienopyridine use was a significant univariable predictor of recurrent events. Furthermore, we have previously shown that thienopyridine use (primarily clopidogrel) does not affect the treatment benefit observed with the addition of vorapaxar in patients with previous MI. 9 limitations There are limitations to this work. Our objective was to identify simple, readily available characteristics that are independently associated with recurrent atherothrombosis. Other previously described risk indicators (eg, angiography, echocardiography, or stress testing) may be useful for risk stratification but may not be obtained routinely in stable outpatients with ischemic heart disease. Additionally, there may be other as-yet unidentified biochemical or genetic characteristics that provide insight into specific mechanisms of risk such as a propensity for vascular thrombosis or increased atherosclerotic disease burden, which should be considered for risk stratification in the future and may offer additional refinement of antithrombotic benefit versus risk of bleeding. Our list of risk indicators is therefore not all inclusive. Nonetheless, the ability of this risk categorization scheme based on frequently occurring characteristics that are usually collected on patients after MI to distinguish populations according to treatment benefit supports its potential to be useful clinically. Finally, our data are derived from a population of patients who were identified for and agreed to participate in a clinical trial; thus, unaccounted selection pressures may influence the generalizability to the general population. For example, women and minorities made up a small proportion of the study population. The presence of other high-risk features for both thrombosis and bleeding should be considered when treatment decisions are being made.
risk assessment and therapeutic intensification in sihD
Risk stratification tools are well validated and recommended by guidelines for use in acute coronary syndromes to assist with prognostication and therapeutic decision making. [10] [11] [12] [13] [14] [15] However, there continues to be a need for similar tools in patients with SIHD. Risk stratification and individualization of therapy among patients with SIHD are emerging as growing needs in the context of the increasing number of evidence-based therapies, balanced against patient preferences and compliance with a large number of medications, potentially smaller absolute gains among patients at lower risk, and the counterbalancing side effects of some therapies (eg, bleeding). The strategy outlined in our study offers clinicians an opportunity to select candidates with the potential for the greatest absolute gains and could be considered for application to other populations and therapeutic interventions for secondary prevention of atherothrombosis. Furthermore, this approach for risk stratification in SIHD may be useful to evaluate the absolute benefitto-risk profile to guide the clinical integration of emerging therapies and could be considered for application in trial design (eg, for the purposes of patient selection at randomization or as a part of an adaptive design strategy). conclusion A practical approach to the categorization of baseline atherothrombotic risk can assist with therapeutic decision making for vorapaxar for secondary prevention after MI.
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